When we talked to the four biologists that make up the unofficial regeneration "cluster" at the University of Kentucky, we learned too many interesting things to cram in the group video. So we made a short video for each of them. Here's more on Randal Voss and axolotls.
Produced by Research Communications at the University of Kentucky.
Alcalde spent her time at the university teaching a graduate seminar on femicide and violence against women. This opportunity to travel and teach abroad allowed Alcalde to investigate new areas of research and explore international experiences separate from those in America.
In this podcast, Alcalde discusses her trip, issues and research around femicide, and how American understandings of femicide contrast with those internationally.
Manasi Malik has just begun her junior year at the University of Kentucky, but the nineteen-year-old biology major has already been published as a lead author on a paper in a prestigious scientific journal.
Graduate students and faculty interested in brushing up on quantitative research methodology, software knowledge or grant-writing techniques should get to know QIPSR. The Quantitative Initiative of Policy and Social Research is an organization committed to enhancing quantitative research across various colleges at the University of Kentucky.
UK History professor and Pulitzer Prize nominated author Tracy A. Campbell's latest book, "The Gateway Arch: A Biography," explores the political and economic history of St. Louis and the origins of the city's most recognized structure. Campbell also serves as co-director of UK's Wendell H. Ford Public Policy Research Center.
At the University of Kentucky, Assistant Professor of Chemistry Edith "Phoebe" Glazer is looking for something more effective at killing cancer cells and less toxic to healthy cells than cisplatin. A platinum-based drug, cisplatin is one of the most commonly used cancer drugs, but leads to nausea and nerve damage. Her alternative uses ruthenium, another transition metal, to build complex molecules. Theses molecules can be "switched on" by light from a fiber-optic probe once they reach their target tumor and would kill only cancerous cells. In January 2013, Glazer received a four-year, $715,000 grant from the American Cancer Society to develop a family of ruthenium molecules to fight different kinds of cancer.